ArticleBioprocess and biosystems engineering2022
Exploring the limits of conventional small-scale CHO fed-batch for accelerated on demand monoclonal antibody production.
Article in Bioprocess and biosystems engineering, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Integrated dual carbon source and TCA intermediate supplementation in fed-batch fermentation of CHO cells for reduced lactate and ammonia accumulation and improved IgG1 monoclonal antibody titre.Bioprocess and biosystems engineering · 2026Article
- Streamlined stable CHO cell line development using droplet microfluidics with image-based monoclonality assessment.Bioprocess and biosystems engineering · 2026Article
- Improving recombinant protein productivity in CHO cells via multi-omics data integration.Bioresources and bioprocessing · 2026Review
- Multivariate analysis of the effects of high seeding density on therapeutic protein production and sialylation in an intensified CHO cell culture process.Bioprocess and biosystems engineering · 2026Article
- Decoding cultured meat manufacturing: a full process model to identify scale-up bottlenecks.Frontiers in nutrition · 2026Article
- Process mapping and optimization study of CHO cell cultures for mAb production using AmbrBioprocess and biosystems engineering · 2025Article
- Establishment of a high-throughput scale-down clone screening platform for intensified fed-batch culture of CHO cells.Biotechnology letters · 2025Article
- Bioprocess biomarker identification and diagnosis for industrial mAb production based on metabolic profiling and multivariate data analysis.Bioprocess and biosystems engineering · 2025Article
- Application of Pseudoinfectious Viruses in Transient Gene Expression in Mammalian Cells: Combining Efficient Expression with Regulatory Compliance.Biomolecules · 2025Article
- Enhancing monoclonal antibody production efficiency using CHO-MK cells and specific media in a conventional fed-batch culture.Cytotechnology · 2025Article
- Optimum blue light exposure: a means to increase cell-specific productivity in Chinese hamster ovary cells.Applied microbiology and biotechnology · 2024Article
- Impact of fed-batch process intensification on the productivity and product quality of two CHO cell lines expressing unique novel molecular format proteins.Bioprocess and biosystems engineering · 2024Article
- Progress in fed-batch culture for recombinant protein production in CHO cells.Applied microbiology and biotechnology · 2023Review
- Status and future of recombinant adeno-associated virus vector manufacturing.Biotechnology progressReview
- Machine learning-assisted clone selection for intensified cell culture processes.Biotechnology progressArticle
- N-1 semi-continuous transient perfusion in shake flask for ultra-high density seeding of CHO cell cultures in benchtop bioreactors.Biotechnology progressArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the field of therapeutic antibody production, diversification of fed-batch strategies is flourishing in response to the market demand. All manufacturing approaches tend to follow the generally accepted dogma of increasing titer since it directly increases manufacturing output. While titer is influenced by the biomass (expressed as IVCD), the culture time and the cell-specific productivity (q
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.